American Century Companies Inc. reduced its stake in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 27.9% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 112,105 shares of the biopharmaceutical company’s stock after selling 43,326 shares during the period. American Century Companies Inc.’s holdings in Vanda Pharmaceuticals were worth $2,929,000 as of its most recent filing with the SEC.
Other hedge funds also recently made changes to their positions in the company. Advisor Group Inc. raised its holdings in Vanda Pharmaceuticals by 66.2% during the 4th quarter. Advisor Group Inc. now owns 2,916 shares of the biopharmaceutical company’s stock worth $77,000 after buying an additional 1,161 shares during the period. LS Investment Advisors LLC raised its holdings in shares of Vanda Pharmaceuticals by 109.3% in the fourth quarter. LS Investment Advisors LLC now owns 3,662 shares of the biopharmaceutical company’s stock valued at $96,000 after purchasing an additional 1,912 shares during the last quarter. Neuburgh Advisers LLC acquired a new stake in shares of Vanda Pharmaceuticals in the fourth quarter valued at approximately $132,000. South Dakota Investment Council acquired a new stake in shares of Vanda Pharmaceuticals in the fourth quarter valued at approximately $167,000. Finally, United Services Automobile Association acquired a new stake in shares of Vanda Pharmaceuticals in the third quarter valued at approximately $211,000. Hedge funds and other institutional investors own 99.33% of the company’s stock.
NASDAQ:VNDA opened at $17.41 on Tuesday. Vanda Pharmaceuticals Inc. has a 1-year low of $13.88 and a 1-year high of $33.44. The firm has a market capitalization of $924.36 million, a P/E ratio of 36.27, a PEG ratio of 5.32 and a beta of 0.51.
Vanda Pharmaceuticals (NASDAQ:VNDA) last released its earnings results on Wednesday, February 13th. The biopharmaceutical company reported $0.19 earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.22. Vanda Pharmaceuticals had a net margin of 13.05% and a return on equity of 9.80%. The business had revenue of $53.04 million during the quarter, compared to analysts’ expectations of $51.56 million. During the same period last year, the business earned ($0.04) earnings per share. The firm’s revenue was up 19.8% on a year-over-year basis. On average, research analysts anticipate that Vanda Pharmaceuticals Inc. will post 0.22 EPS for the current fiscal year.
In related news, CFO James Patrick Kelly sold 4,976 shares of the firm’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $20.15, for a total value of $100,266.40. Following the completion of the transaction, the chief financial officer now directly owns 218,497 shares of the company’s stock, valued at $4,402,714.55. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Mihael Hristos Polymeropoulos sold 6,500 shares of the firm’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $20.22, for a total transaction of $131,430.00. Following the completion of the transaction, the chief executive officer now directly owns 1,217,136 shares of the company’s stock, valued at $24,610,489.92. The disclosure for this sale can be found here. Insiders sold 59,274 shares of company stock valued at $1,164,127 over the last three months. 7.80% of the stock is owned by company insiders.
A number of analysts have recently issued reports on VNDA shares. Oppenheimer lowered their price objective on shares of Vanda Pharmaceuticals from $29.00 to $21.00 in a report on Thursday, February 14th. ValuEngine upgraded shares of Vanda Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, February 14th. Stifel Nicolaus reiterated a “buy” rating and issued a $40.00 price objective on shares of Vanda Pharmaceuticals in a report on Thursday, February 14th. BidaskClub downgraded shares of Vanda Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, January 24th. Finally, Cantor Fitzgerald set a $43.00 price objective on shares of Vanda Pharmaceuticals and gave the company a “buy” rating in a report on Monday, December 17th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and six have issued a buy rating to the company. Vanda Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $34.00.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.
Want to see what other hedge funds are holding VNDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vanda Pharmaceuticals Inc. (NASDAQ:VNDA).
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.